The FDA’s Overton Window Problem
Heidi Overton’s confirmation hearing featured discussion of mifepristone and vaccines. But the agency’s problems go way beyond that.

You’re reading The TNR Blue Book. Get daily scoops, strategy, and developments inside the liberal ideas factory delivered right to your inbox. Sign up for free.
Inside Washington
The FDA’s Overton window problem
On Thursday, Republican Senator Susan Collins, a self-described abortion rights supporter, asked not a single question about abortion during the hearing for Food and Drug Administration commissioner nominee Heidi Overton. That, along with testy exchanges with Democrats over Overton’s vaccine views, is likely to be the primary takeaway from the confirmation hearing.
But while Overton’s past comments on mifepristone and vaccines receive top billing, less attention is being given to the larger dysfunction that has plagued the FDA since Trump’s second inauguration.
Democratic senators, unlike Collins, took a strong line on abortion on Thursday. “I am not going to support someone who doesn’t support a woman’s right to make her own choices,” Senator Patty Murray of Washington, who sits on the Health, Education, Labor, and Pensions Committee, told The New Republic. If confirmed to lead the FDA, Overton will inherit an ongoing study of mifepristone’s safety, which could be an opening step for the Trump administration to restrict its use. In her past role at the MAGA-aligned America First Policy Institute, Overton wrote an article claiming that medication-assisted abortion is “dangerous to women.” On Thursday, she dodged questions about whether she believes mifepristone is safe, instead saying that she agrees with “the statutory standards of safety and efficacy” set by the FDA.
Vaccines were another major issue during the hearing, particularly because of Overton’s association with Trump’s and Health Secretary RFK Jr.’s rhetoric on vaccine safety. Last month, Overton stood beside the two men when they suggested that combination vaccines could cause autism. Senator Maggie Hassan of New Hampshire pressed Overton on vaccines, asking her if she believed Trump could “ever be wrong about something.” Overton didn’t answer the question directly, instead saying that she “had the privilege of working for the president.”
Overton also attended Trump’s Oval Office signing of an executive order to reduce the childhood vaccination schedule and split the MMR vaccine into multiple shots. During the event, Trump also called the MMR vaccine “potentially quite lethal.” Overton denied that the vaccine is lethal at Thursday’s hearing, but that disavowal came too late for some senators. “She should have corrected the president in public when he was putting out bad information about the efficacy of vaccines,” said Senator Ed Markey of Massachusetts, who sits on the HELP Committee. “When he said it was ‘lethal,’ she should have corrected him right there.”
“She seems like a very nice person, but I don’t think she’s the person who should hold that job,” Senator Bernie Sanders, the ranking member of HELP, told The New Republic. “We need people who have the courage to stand up to President Trump. I’m not sure that’s her.”
Overton stands to take over a deeply troubled federal agency. The FDA’s current crisis began early on in President Trump’s second term, when nearly one-fifth of the agency’s workforce (around 4,000 employees) left due to firings or buyouts. Since then, a number of high-profile foodborne illnesses and recalls have popped up across the country, which some experts and politicians have suggested could have been exacerbated by cuts at the FDA and the Centers for Disease Control and Prevention.
Staff turnover has been rampant at the FDA. In 2025, around 90 percent of senior FDA personnel reportedly left the agency, leaving just three experienced senior leaders in place. Since Trump’s inauguration, the Center for Biologics Evaluation and Research, which focuses on the development of vaccines and drugs for rare diseases, has had six different directors. In May, the then head of the FDA, Marty Makary, resigned after just a year at the helm. His tenure was marked by political interference into the FDA’s decision-making. Anti-abortion groups criticized Makary for not advancing the review of mifepristone, while e-cigarette company executives complained to Trump that Makary wasn’t approving their products fast enough. The vaccine chief under Makary, Vinay Prasad, left the agency twice after right-wing activists like Laura Loomer and biotech executives alike criticized him.
In addition to their concerns about abortion and vaccines, some Democratic senators worry that Overton would continue this pattern of politicization within the agency. “I just don’t think [Overton is] committed to ending political interference in the FDA decision-making process,” Senator Chris Murphy of Connecticut, who sits on the HELP Committee, told The New Republic. “She’s been given that job specifically to protect political interference.”
—Emma Janssen
Outside Washington
The charter companies running ICE deportation flights out of Akron-Canton Regional Airport, the Ohio Capital Journal reports, owe the airport a combined $46,513 for landings between the end of April and early September—of which $33,927 is past due. In recent weeks, “Akron-Canton has become a Great Lakes hub,” reports Doug Oplinger, who has been staking out the airport while scrutinizing flight records. He finds “planes landing here in the evening, often from a major ICE prison and deportation center in Alexandria, Louisiana, and on occasion directly from Tapachula, Mexico, the end point for many of the deportees.” Oplinger writes that attempts to get comment from the companies involved, ICE media relations, and multiple other parties have been “largely unanswered.”
In case you missed it: The Arizona Republic’s Stacey Barchenger went hunting for the alleged Democrats supporting Republican Andy Biggs against Katie Hobbs in the Arizona governor’s race—the ones mentioned in a slew of “Democrats for Biggs” signs that have proliferated recently. The signs, she notes, are paid for by conservative group Turning Point USA—the late Charlie Kirk’s group. “Biggs couldn’t name a Democrat who supports his campaign—but he said they are out there” and referred Barchenger to “whoever’s putting up those signs.” Barchenger duly contacted Turning Point spokespeople, who “did not respond to multiple questions about … whether any coalition of Democrats backing Republican Andy Biggs for governor exists.” Read the full story for all this and significant further shenanigans.
—Heather Souvaine Horn
The Ideas Factory
Public Citizen publishes a statement on the report recently released by Senators Chuck Schumer and Sheldon Whitehouse on the fossil fuel industry’s influence in the Trump administration. The report highlighted, among other things, the policy “wish lists” the industry compiled for the administration, many items of which were quickly enacted. “Every American family struggling with high costs is suffering because of the corrupt relationship between Donald Trump and the fossil fuel industry,” says Public Citizen’s climate program director, David Arkush, in the group’s statement.
Friday, September 25, at noon, the Roosevelt Institute holds its Fall Policy Summit with Roosevelt Network members “fighting for academic freedom, democracy, and LGBTQ+ rights; working with local organizations to explore how city governments can better support workers; and traveling across their states to hear directly from farmers about the economy they want to see.” Interested viewers can join on Zoom to “hear from Network members about what they’re working on and how they’re turning ideas into action.”
—Heather Souvaine Horn
In Closing
Good Week: Abdul El-Sayed
The Democratic candidate for Senate in Michigan got two new polls this week offering him good news, and boy is this welcome for Democrats. A Suffolk poll found El-Sayed leading GOPer Mike Rogers by 47–40. And the gold-standard New York Times survey found him up by 49–44. Notably, the latter found him clearing 40 percent with working-class whites, a key threshold. With many analysts wondering if he’ll win enough of this demographic to prevail in the Midwestern state, all this will help quiet Democratic panic about El-Sayed’s chances.
Bad Week: Troy Jackson
The aforementioned gold-standard Times poll also finds this week that Maine Senator Susan Collins is leading her Democratic challenger by three points, 49–46. What really jumps out is that Jackson’s support among non-college voters is an abysmal 34 percent. True, a recent CNN poll showed Jackson up three points, but taken altogether, this is way too close for comfort in such a pro-Democratic national environment and in a state that Trump lost by seven points in 2024. What’s more, the CNN poll also finds Jackson at 38 percent with non-college voters, suggesting this group is a real problem for him. That’s especially noteworthy, since one of this fifth-generation logger’s biggest political selling points is his roots in the rural working class.
—Greg Sargent
Political Trivia Question of the Day
Tomorrow, Donald Trump will be in Knoxville for the Tennessee-Texas game. Some years ago, a president infamously waded into a heated debate over who was the number one team in college football. This was back when presidents didn’t offer their opinions on every topic under the sun, and it was a big controversy. Whose fans did he please, and whose did he infuriate? (Sign up for The TNR Blue Book to find the answer in Tuesday’s newsletter.)
—Michael Tomasky







